Paris Meeting Puts Precision Hepatology at the Center of Care
The first Annual Paris International Liver Meeting, held January 19-21, 2026, captured a field in rapid motion. Chronic liver disease is no longer being discussed only in terms of detection, staging, and surveillance. The conversation has shifted toward mechanism-based treatment, risk-adapted monitoring, and interventions that aim to change the course of disease rather than simply follow its complications.
This shift is most visible in MASLD and MASH, where approved disease-modifying therapies have moved the field beyond the long era of supportive management and lifestyle advice alone. Resmetirom and semaglutide are now approved for MASH with F2-F3 fibrosis, a milestone that changes how clinicians think about progressive steatotic liver disease. It also changes the therapeutic expectations at the bedside. Patients with fibrotic disease are no longer confined to counseling and surveillance while the disease advances; treatment is now entering the clinic with biochemical and histologic intent.
A second wave of agents is already pressing forward. The pipeline includes anti-fibrotic signals from FGF21 analogs, pan-PPAR agonists, and incretin-based dual and triple agonists. These agents matter because fibrosis is the key determinant of clinical outcome in MASH, and a drug class that can blunt inflammation, metabolic stress, and fibrogenic signaling has a plausible route to altering long-term prognosis. The challenge now is not simply whether the liver fat decreases. The more meaningful question is whether treatment can reliably slow or reverse the scarring that drives cirrhosis, portal hypertension, and cancer risk.
Non-Invasive Testing Has Moved Beyond Diagnosis
Non-invasive tests have expanded well past their original role as alternatives to biopsy. In this meeting framework, they now serve several functions at once: prognostic stratification, screening of at-risk populations, treatment selection, and monitoring of response. That evolution is clinically important because it aligns liver care with a more scalable model. Fibrosis assessment can be repeated, risk can be tracked over time, and treatment can be directed toward the patients most likely to benefit.
The same principle extends beyond MASLD. In primary biliary cholangitis and portal hypertension, non-invasive tools are increasingly integrated into routine decision-making, a theme reflected in the Baveno Consensus Workshops. The practical value is substantial. Patients can be identified earlier, complications can be anticipated sooner, and the burden of repeated invasive assessment can be reduced when validated biomarkers and elastography-based strategies are used appropriately.
In cholestatic liver disease, this shift is especially relevant because disease activity does not always track neatly with symptoms. Biochemical response, fibrosis risk, and symptom burden may diverge. Non-invasive stratification offers a way to organize that complexity into a treatment plan instead of waiting for decompensation to make the diagnosis obvious.
HBV and HDV Are Moving Toward Cure-Oriented Treatment Paths
Hepatitis B management is becoming more deliberate and less uniform. Simplified treatment algorithms based on fibrosis and viral load are gaining ground, supported by biomarkers that can help stratify risk and guide safe treatment discontinuation. The direction of travel is toward functional cure strategies rather than indefinite treatment for all patients under a broad umbrella. In practical terms, that means more individualized decisions about who needs therapy now, who can be observed, and who may eventually stop treatment safely.
Hepatitis D is following a similar but more urgent trajectory. Bulevirtide has changed the therapeutic conversation by offering a suppressive option in a disease that has long been difficult to treat. At the same time, novel HBsAg-targeting and RNA-silencing therapies are pushing the field toward potential curative strategies. HDV has traditionally represented one of the most severe forms of viral liver disease, so even incremental control has meaningful clinical consequences. If viral suppression can be coupled to deeper antigen reduction, the prospect of durable remission becomes more realistic than it once was.
PBC Gains Options, But Care Gaps Remain Large
Primary biliary cholangitis remains a disease in which therapeutic progress and real-world under-treatment coexist. Novel PPAR agonists are improving cholestatic biochemistry and pruritus, and individualised risk stratification is now central to management. The biology is logical: by modulating metabolic and inflammatory pathways, these agents can influence both liver tests and the symptom burden that often dominates daily life for patients.
Yet treatment access and uptake remain insufficient. Fewer than half of eligible patients receive second-line therapy. That shortfall is not a small implementation problem; it directly affects the number of patients who remain biochemically uncontrolled and at continued risk for progression. Fatigue also remains a major unmet clinical need, and no biomarker or drug response metric has fully solved that problem. In PBC, improvement in laboratory values does not automatically translate into relief of the most disabling symptoms.
PSC Still Lacks a Disease-Modifying Answer
Primary sclerosing cholangitis continues to resist the therapeutic advances seen in neighboring liver diseases. No approved disease-modifying treatments are currently available. For clinicians, that remains one of hepatology’s most frustrating gaps, because PSC combines chronic cholestatic injury, biliary stricturing, malignancy risk, and limited pharmacologic options into a single difficult syndrome. The absence of an approved therapy means surveillance, complication management, and transplant planning still dominate care.
This contrast with MASH and PBC is stark. While some parts of hepatology are entering a precision-treatment era, PSC remains largely dependent on supportive and procedural strategies rather than a validated drug that alters its natural history.
HCC Survival Is Changing in Selected Immunotherapy Responders
For hepatocellular carcinoma, immunotherapy combinations are producing unprecedented long-term survival in selected patient populations. This is a major development because HCC has long been defined by late diagnosis, underlying cirrhosis, and restricted systemic options. Combination immunotherapy is beginning to change expectations in patients who can tolerate and respond to treatment.
The biological rationale is straightforward. By engaging the immune system against tumor cells, combination regimens can generate deeper and more durable anti-tumor activity than older systemic approaches. In a disease shaped by immune escape, chronic inflammation, and a cirrhotic microenvironment, that strategy has a clear mechanistic basis. The most important caveat is selection: these gains apply to selected populations, not all patients with HCC, and liver function still strongly conditions treatment feasibility.
Hepatology Is Entering a Mechanism-Driven Era
Across MASLD, viral hepatitis, cholestatic disease, portal hypertension, and HCC, the meeting’s message was consistent. Hepatology is moving away from one-size-fits-all management and toward care built around disease mechanism, fibrosis stage, biomarker selection, and risk-adapted treatment intensity. Approved therapies now exist for MASH with F2-F3 fibrosis. HBV and HDV are being rethought through simplified and cure-oriented frameworks. PBC has new pharmacologic options, even as access gaps persist. PSC still lacks a disease-modifying drug, and HCC survival is improving in carefully selected patients receiving immunotherapy combinations.
The next test is not whether the field has momentum. It does. The real test is whether these new tools can be deployed early enough, broadly enough, and precisely enough to change hard outcomes in routine practice rather than only in expert centers.